New hope for tough blood cancers: first human trial launches
NCT ID NCT06950034
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called STX-0712 in people with advanced types of blood cancer (CMML or AML) who have run out of standard treatments. The main goal is to find a safe dose and see how the body handles the drug. About 105 participants will take part in this early-phase trial.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MONOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
DFCI
RECRUITINGBoston, Massachusetts, 02215, United States
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
Mayo Clinic
RECRUITINGRochester, Minnesota, 55905, United States
-
Moffitt
RECRUITINGTampa, Florida, 12902, United States
-
OHSU
RECRUITINGPortland, Oregon, 97239, United States
-
Stanford University
RECRUITINGStanford, California, 94305, United States
-
Vanderbilt University
NOT_YET_RECRUITINGNashville, Tennessee, 37232, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Could muscle loss predict blood cancer outcomes?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?